Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G. Pirosa MC, et al. Among authors: mauro e. Chemotherapy. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29. Chemotherapy. 2018. PMID: 30372691
Intermediate dose etoposide plus G-CSF 16 g/kg is more effective than cyclophosphamide 4 g/m(2) plus G-CSF 10 g/kg in PBSC mobilization of lymphoma patients.
Milone G, Leotta S, Battiato K, Murgano P, Mercurio S, Strano A, Poidomani M, Coppoletta S, Mauro E, Avola G, Pinto V, Camuglia MG, Giustolisi R. Milone G, et al. Among authors: mauro e. Leuk Lymphoma. 2007 Oct;48(10):1950-60. doi: 10.1080/10428190701573240. Leuk Lymphoma. 2007. PMID: 17917963 Clinical Trial.
Desensitization with plasma exchange in a patient with human leukocyte antigen donor-specific antibodies before T-cell-replete haploidentical transplantation.
Bramanti S, Nocco A, Mauro E, Milone G, Morabito L, Sarina B, Crocchiolo R, Timofeeva I, Capizzuto R, Carlo-Stella C, Santoro A, Castagna L. Bramanti S, et al. Among authors: mauro e. Transfusion. 2016 May;56(5):1096-1100. doi: 10.1111/trf.13523. Epub 2016 Mar 28. Transfusion. 2016. PMID: 27021516
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database.
Gozzo L, Vetro C, Brancati S, Longo L, Vitale DC, Romano GL, Mauro E, Fiumara PF, Maugeri C, Parisi MS, Dulcamare I, Garibaldi B, Duminuco A, Palumbo GA, Di Raimondo F, Drago F. Gozzo L, et al. Among authors: mauro e. Front Pharmacol. 2021 Nov 11;12:748766. doi: 10.3389/fphar.2021.748766. eCollection 2021. Front Pharmacol. 2021. PMID: 34899303 Free PMC article.
Potential clinical impact of T-cell lymphocyte kinetics monitoring in patients with B cell precursors acute lymphoblastic leukemia treated with blinatumomab: a single-center experience.
Duminuco A, Markovic U, Parrinello NL, Lo Nigro L, Mauro E, Vetro C, Parisi M, Maugeri C, Fiumara PF, Milone G, Romano A, Di Raimondo F, Leotta S. Duminuco A, et al. Among authors: mauro e. Front Immunol. 2023 Sep 22;14:1195734. doi: 10.3389/fimmu.2023.1195734. eCollection 2023. Front Immunol. 2023. PMID: 37809082 Free PMC article.
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
Leotta S, Markovic U, Duminuco A, Mulè A, Porretto F, Federico V, Gentile M, Pastore D, Nigro LL, Selleri C, Serio B, Calafiore V, Patti C, Mauro E, Vetro C, Maugeri C, Parisi M, Fiumara P, Parrinello L, Marino S, Scuderi G, Garibaldi B, Musso M, Renzo ND, Vigna E, Martino EA, Raimondo FD, Milone G. Leotta S, et al. Among authors: mauro e. Ann Hematol. 2024 Sep;103(9):3701-3712. doi: 10.1007/s00277-024-05725-9. Epub 2024 Apr 13. Ann Hematol. 2024. PMID: 38609726
348 results